Bernadette Gaffney

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Metastatic triple-negative breast cancer comprises 12%-17% of breast cancers and carries a poor prognosis relative to other breast cancer subtypes. Treatment options in this disease are largely limited to systemic chemotherapy. A majority of clinical studies assessing efficacy of targeted therapeutics (e.g., the mammalian target of rapamycin [mTOR](More)
  • 1